Research ArticleArticle
Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis
Michelle J. Ormseth, Joseph F. Solus, Kasey C. Vickers, Annette M. Oeser, Paolo Raggi and C. Michael Stein
The Journal of Rheumatology August 2015, jrheum.150232; DOI: https://doi.org/10.3899/jrheum.150232
Michelle J. Ormseth
From the Department of Medicine in the divisions of Rheumatology, Clinical Pharmacology, and Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA, and the Department of Medicine in the Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. Funding from the Arthritis Foundation Clinical to Research Transition Award, American College of Rheumatology Research Foundation; US National Institutes of Health Grants: P60 AR056116, P01HL116263, KL2TR000446, and Clinical and Translational Science Award UL1TR000445 from the US National Center for Advancing Translational Sciences. This article’s contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. M.J. Ormseth, MD, MSCI; J.F. Solus, PhD; K.C. Vickers, PhD; A.M. Oeser, BS, MLAS, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center; P. Raggi, MD, Department of Medicine and Division of Cardiology, University of Alberta; C.M. Stein, MD, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center. M.J. Ormseth and J.F. Solus contributed equally to this work. Address correspondence to Dr. M.J. Ormseth, 1161 21st Ave. South, T-3113 MCN, Nashville, Tennessee 37232-2681, USA. E-mail: michelle.ormseth@vanderbilt.edu. Accepted for publication June 4, 2015.
Joseph F. Solus
From the Department of Medicine in the divisions of Rheumatology, Clinical Pharmacology, and Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA, and the Department of Medicine in the Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. Funding from the Arthritis Foundation Clinical to Research Transition Award, American College of Rheumatology Research Foundation; US National Institutes of Health Grants: P60 AR056116, P01HL116263, KL2TR000446, and Clinical and Translational Science Award UL1TR000445 from the US National Center for Advancing Translational Sciences. This article’s contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. M.J. Ormseth, MD, MSCI; J.F. Solus, PhD; K.C. Vickers, PhD; A.M. Oeser, BS, MLAS, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center; P. Raggi, MD, Department of Medicine and Division of Cardiology, University of Alberta; C.M. Stein, MD, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center. M.J. Ormseth and J.F. Solus contributed equally to this work. Address correspondence to Dr. M.J. Ormseth, 1161 21st Ave. South, T-3113 MCN, Nashville, Tennessee 37232-2681, USA. E-mail: michelle.ormseth@vanderbilt.edu. Accepted for publication June 4, 2015.
Kasey C. Vickers
From the Department of Medicine in the divisions of Rheumatology, Clinical Pharmacology, and Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA, and the Department of Medicine in the Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. Funding from the Arthritis Foundation Clinical to Research Transition Award, American College of Rheumatology Research Foundation; US National Institutes of Health Grants: P60 AR056116, P01HL116263, KL2TR000446, and Clinical and Translational Science Award UL1TR000445 from the US National Center for Advancing Translational Sciences. This article’s contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. M.J. Ormseth, MD, MSCI; J.F. Solus, PhD; K.C. Vickers, PhD; A.M. Oeser, BS, MLAS, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center; P. Raggi, MD, Department of Medicine and Division of Cardiology, University of Alberta; C.M. Stein, MD, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center. M.J. Ormseth and J.F. Solus contributed equally to this work. Address correspondence to Dr. M.J. Ormseth, 1161 21st Ave. South, T-3113 MCN, Nashville, Tennessee 37232-2681, USA. E-mail: michelle.ormseth@vanderbilt.edu. Accepted for publication June 4, 2015.
Annette M. Oeser
From the Department of Medicine in the divisions of Rheumatology, Clinical Pharmacology, and Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA, and the Department of Medicine in the Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. Funding from the Arthritis Foundation Clinical to Research Transition Award, American College of Rheumatology Research Foundation; US National Institutes of Health Grants: P60 AR056116, P01HL116263, KL2TR000446, and Clinical and Translational Science Award UL1TR000445 from the US National Center for Advancing Translational Sciences. This article’s contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. M.J. Ormseth, MD, MSCI; J.F. Solus, PhD; K.C. Vickers, PhD; A.M. Oeser, BS, MLAS, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center; P. Raggi, MD, Department of Medicine and Division of Cardiology, University of Alberta; C.M. Stein, MD, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center. M.J. Ormseth and J.F. Solus contributed equally to this work. Address correspondence to Dr. M.J. Ormseth, 1161 21st Ave. South, T-3113 MCN, Nashville, Tennessee 37232-2681, USA. E-mail: michelle.ormseth@vanderbilt.edu. Accepted for publication June 4, 2015.
Paolo Raggi
From the Department of Medicine in the divisions of Rheumatology, Clinical Pharmacology, and Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA, and the Department of Medicine in the Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. Funding from the Arthritis Foundation Clinical to Research Transition Award, American College of Rheumatology Research Foundation; US National Institutes of Health Grants: P60 AR056116, P01HL116263, KL2TR000446, and Clinical and Translational Science Award UL1TR000445 from the US National Center for Advancing Translational Sciences. This article’s contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. M.J. Ormseth, MD, MSCI; J.F. Solus, PhD; K.C. Vickers, PhD; A.M. Oeser, BS, MLAS, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center; P. Raggi, MD, Department of Medicine and Division of Cardiology, University of Alberta; C.M. Stein, MD, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center. M.J. Ormseth and J.F. Solus contributed equally to this work. Address correspondence to Dr. M.J. Ormseth, 1161 21st Ave. South, T-3113 MCN, Nashville, Tennessee 37232-2681, USA. E-mail: michelle.ormseth@vanderbilt.edu. Accepted for publication June 4, 2015.
C. Michael Stein
From the Department of Medicine in the divisions of Rheumatology, Clinical Pharmacology, and Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA, and the Department of Medicine in the Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. Funding from the Arthritis Foundation Clinical to Research Transition Award, American College of Rheumatology Research Foundation; US National Institutes of Health Grants: P60 AR056116, P01HL116263, KL2TR000446, and Clinical and Translational Science Award UL1TR000445 from the US National Center for Advancing Translational Sciences. This article’s contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health. M.J. Ormseth, MD, MSCI; J.F. Solus, PhD; K.C. Vickers, PhD; A.M. Oeser, BS, MLAS, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center; P. Raggi, MD, Department of Medicine and Division of Cardiology, University of Alberta; C.M. Stein, MD, Department of Medicine and Division of Clinical Pharmacology, Vanderbilt University Medical Center. M.J. Ormseth and J.F. Solus contributed equally to this work. Address correspondence to Dr. M.J. Ormseth, 1161 21st Ave. South, T-3113 MCN, Nashville, Tennessee 37232-2681, USA. E-mail: michelle.ormseth@vanderbilt.edu. Accepted for publication June 4, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis
Michelle J. Ormseth, Joseph F. Solus, Kasey C. Vickers, Annette M. Oeser, Paolo Raggi, C. Michael Stein
The Journal of Rheumatology Aug 2015, jrheum.150232; DOI: 10.3899/jrheum.150232
Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis
Michelle J. Ormseth, Joseph F. Solus, Kasey C. Vickers, Annette M. Oeser, Paolo Raggi, C. Michael Stein
The Journal of Rheumatology Aug 2015, jrheum.150232; DOI: 10.3899/jrheum.150232